Overview

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Status:
Terminated

Trial end date:
2017-11-06

Target enrollment:

Participant gender:

Summary

This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Azacitidine